Molecular Analysis in a Glioblastoma Cohort—Results of a
Prospective Analysis

Liverana Lauretti; Tonia Cenci; Nicola Montano; Martina Offi; Martina Giordano; Valerio M. Caccavella; Antonella Mangraviti; Ludovico Agostini; Alessandro Olivi; Lucia Gabriele; Luigi M. Larocca; Roberto Pallini; Maurizio Martini; Quintino Giorgio D'Alessandris

doi:10.3390/jpm12050685

Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis

Liverana Lauretti, Tonia Cenci, Nicola Montano, Martina Offi, Martina Giordano, Valerio M. Caccavella, Antonella Mangraviti, Ludovico Agostini, Alessandro Olivi, Lucia Gabriele, Luigi M. Larocca, Roberto Pallini^*, Maurizio Martini, Quintino Giorgio D'Alessandris

^*Autore corrispondente per questo lavoro

IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively\r\nactivated oncogenic receptor, in glioblastoma is controversial. We performed a prospective\r\nstudy enrolling 355 patients operated on for de novo glioblastoma at a large academic center.\r\nThe molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression,\r\nwas assessed. Standard parameters (age, clinical status and extent of surgical resection) were\r\nconfirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved\r\nsurvival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened\r\nprognosis. Interestingly, female sex was associated with a better outcome. Such findings are of\r\ninterest for the design of future trials.

Lingua originale	Inglese
pagine (da-a)	N/A-N/A
Numero di pagine	8
Rivista	Journal of Personalized Medicine
Volume	12
Numero di pubblicazione	5
DOI	https://doi.org/10.3390/jpm12050685
Stato di pubblicazione	Pubblicato - 2022

All Science Journal Classification (ASJC) codes

Medicina (varie)

Keywords

EGFRvIII
VEGF
female
glioblastoma
trial population

Accesso al documento

10.3390/jpm12050685

Altri file e collegamenti

Cita questo

Lauretti, L., Cenci, T., Montano, N., Offi, M., Giordano, M., Caccavella, V. M., Mangraviti, A., Agostini, L., Olivi, A., Gabriele, L., Larocca, L. M., Pallini, R., Martini, M., & D'Alessandris, Q. G. (2022). Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis. Journal of Personalized Medicine, 12(5), N/A-N/A. https://doi.org/10.3390/jpm12050685

@article{57184671b878420dbfd9077cf7413fd2,

title = "Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis",

abstract = "The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively\textbackslash{}r\textbackslash{}nactivated oncogenic receptor, in glioblastoma is controversial. We performed a prospective\textbackslash{}r\textbackslash{}nstudy enrolling 355 patients operated on for de novo glioblastoma at a large academic center.\textbackslash{}r\textbackslash{}nThe molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression,\textbackslash{}r\textbackslash{}nwas assessed. Standard parameters (age, clinical status and extent of surgical resection) were\textbackslash{}r\textbackslash{}nconfirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved\textbackslash{}r\textbackslash{}nsurvival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened\textbackslash{}r\textbackslash{}nprognosis. Interestingly, female sex was associated with a better outcome. Such findings are of\textbackslash{}r\textbackslash{}ninterest for the design of future trials.",

keywords = "EGFRvIII, VEGF, female, glioblastoma, trial population, EGFRvIII, VEGF, female, glioblastoma, trial population",

author = "Liverana Lauretti and Tonia Cenci and Nicola Montano and Martina Offi and Martina Giordano and Caccavella, \{Valerio M.\} and Antonella Mangraviti and Ludovico Agostini and Alessandro Olivi and Lucia Gabriele and Larocca, \{Luigi M.\} and Roberto Pallini and Maurizio Martini and D'Alessandris, \{Quintino Giorgio\}",

year = "2022",

doi = "10.3390/jpm12050685",

language = "English",

volume = "12",

pages = "N/A--N/A",

journal = "Journal of Personalized Medicine",

issn = "2075-4426",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis

AU - Lauretti, Liverana

AU - Cenci, Tonia

AU - Montano, Nicola

AU - Offi, Martina

AU - Giordano, Martina

AU - Caccavella, Valerio M.

AU - Mangraviti, Antonella

AU - Agostini, Ludovico

AU - Olivi, Alessandro

AU - Gabriele, Lucia

AU - Larocca, Luigi M.

AU - Pallini, Roberto

AU - Martini, Maurizio

AU - D'Alessandris, Quintino Giorgio

PY - 2022

Y1 - 2022

N2 - The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively\r\nactivated oncogenic receptor, in glioblastoma is controversial. We performed a prospective\r\nstudy enrolling 355 patients operated on for de novo glioblastoma at a large academic center.\r\nThe molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression,\r\nwas assessed. Standard parameters (age, clinical status and extent of surgical resection) were\r\nconfirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved\r\nsurvival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened\r\nprognosis. Interestingly, female sex was associated with a better outcome. Such findings are of\r\ninterest for the design of future trials.

AB - The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively\r\nactivated oncogenic receptor, in glioblastoma is controversial. We performed a prospective\r\nstudy enrolling 355 patients operated on for de novo glioblastoma at a large academic center.\r\nThe molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression,\r\nwas assessed. Standard parameters (age, clinical status and extent of surgical resection) were\r\nconfirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved\r\nsurvival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened\r\nprognosis. Interestingly, female sex was associated with a better outcome. Such findings are of\r\ninterest for the design of future trials.

KW - EGFRvIII

KW - VEGF

KW - female

KW - glioblastoma

KW - trial population

KW - EGFRvIII

KW - VEGF

KW - female

KW - glioblastoma

KW - trial population

UR - https://publicatt.unicatt.it/handle/10807/201844

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85129907771&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85129907771&origin=inward

U2 - 10.3390/jpm12050685

DO - 10.3390/jpm12050685

M3 - Article

SN - 2075-4426

VL - 12

SP - N/A-N/A

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

IS - 5

ER -